1:1
Canonical splice-site TTN variants (TTNcsv) are linked to cardiac conduction disturbances, producing mostly non-truncating transcripts, unlike DCM-associated TTNcsv. These findings highlight variant-specific transcriptional effects and their potential role in cardiac phenotypes.
Aims

Truncating variations in the titin gene (TTNtv) are the most common genetic cause of dilated cardiomyopathy (DCM) and have been implicated in various arrhythmic and heart failure phenotypes. Nonetheless, predicting the pathogenicity of a distinct subtype of TTNtv, canonical splice-site variations (TTNcsv), remains challenging. Furthermore, the precise transcriptional and phenotypic consequences associated with TTNcsv remain unclear. We evaluated the transcriptional profiles of TTN in vitro, focusing on TTNcsv found in patients with cardiac dysfunction, and compared them with their phenotypic manifestations.

Methods and results

Genome-wide linkage analysis, whole-exome sequencing, and whole-genome sequencing were performed on a five-generation family with cardiac conduction disturbance (CCD). In addition, whole-genome sequencing was performed on 402 Japanese biobank patients with cardiomyopathy (CM) or unidentified cardiac dysfunction. Transcriptional profiles of TTNcsv were evaluated by RNA-Seq of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and endomyocardial biopsy specimens, and by minigene assays. A rare segregating TTNcsv (c.49049-2A>C) was identified in the five-generation family with CCD. RNA-Seq and minigene assays revealed complex aberrant TTN splicing transcripts: predominantly non-truncating transcripts caused by an 18 bp in-frame deletion (83–90%) and minor truncating transcripts (10–17%). Two additional TTNcsv were identified in biobank participants by whole-genome sequencing. A minigene assay of TTNcsv c.67348+1G>A, identified in a CCD patient with mild cardiac dysfunction, revealed predominantly non-truncating transcripts (95%), caused by retention of a 90 bp in-frame intron, along with 5% truncating TTN transcripts, caused by a 50 bp frameshift deletion, mirroring the TTNcsv observed in the familial CCD. In contrast, the DCM-associated TTNcsv c.67637-2A>G generated 87% truncating TTN transcripts, attributed to frameshift intron retention and cryptic splicing.

Conclusion

The clinical data from this family suggest a close association between TTNcsv and CCD, which may involve an increase in non-truncating transcripts. Further studies are required to determine their precise relationship and the underlying mechanisms.

Year of publication

2025

Source

Cardiovascular Research, Volume 121, Issue 11, September 2025, Pages 1712–1721

Link to cite

Acces to Link >

Author

Taisuke Ishikawa , Hiroki Kimoto , Akiko Seki , Manabu Shirai , Kenta Uto , Takeru Makiyama , Takeshi Kitai , Hiroyuki Mishima , Daniel Trujillano , Floriane Simonet , Estelle Baron , Pierre Lindenbaum , Florence Kyndt , Adeline Goudal , Norihide Fukushima , Tomoyuki Fujita , Kinta Hatakeyama , Nobuhisa Hagiwara , Koh-ichiro Yoshiura , Richard Redon , Christian Dina , Xavier Estivill , Stephan Ossowski , Mathieu Courtheix , Vincent Probst , Julien Barc , Jean-Jacques Schott , Naomasa Makita

You might also be interested in

European Parliament research service assessment, published in February 2026, identifies 31 measures that could form an EU rare disease action plan, highlighting European Reference Networks and cross-border collaboration including ERDERA as drivers of EU added value.
This study investigates possible measures that could be taken at EU level to address these challenges. It finds significant European added value in harmonising coordination and access across the 27 Member States, mainly in terms of improved diagnostic tools and availability of medical treatment, better health outcomes, particularly lower infant mortality, and improved well-being of family members and caregivers.
28 February, across Europe and beyond: one year into delivery, ERDERA is advancing towards shorten diagnostic journeys and improved therapies for people living with a rare disease.
This meeting will focus on practical approaches to phenotyping and diagnosis in undiagnosed conditions, including how to define next steps when a diagnosis remains uncertain, and how to strengthen pathways and collaboration around undiagnosed care.